Skip to content

Mindfulness-based eating in obesity and anxiety: a randomized controlled trial and feasibility assessment.

Natasha Kim de Oliveira da Fonseca, Gabriela Rocha Dos Santos, Gabrielle Terezinha Foppa, Gabriella Nunes da Luz Morelo, Artur Zanelatto Santos, Gibson Weydmann, Brunna Boaventura, Stuart William Flint, Luciana Conceição Antunes, Elisa Brietzke, Gisele Gus Manfro

Lancet Regional Health. Americas July 15, 2026 DOI: 10.1016/j.lana.2026.101541 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 70
Population Adults living with obesity and generalized anxiety disorder
Interventions Mindfulness-based Eating (ME) intervention asynchronous health educational video control
Duration Five-week intervention
Measures Go/No Go test, Weight Bias Internalization scale (WBIS), Body Appreciation Scale-2 (BAS2), Self-Compassion Scale (SCS), GAD7, PHQ9, Difficulties in Emotion Regulation Scale (DERS), Other As Shamer scale (OAS), Early Memories of Warmth and Safeness Scale (EMWSS), ER5FP, Mindful Eating Questionnaire (MEQ), Binge Eating Scale (BES), Barratt Impulsiveness Scale (BIS)
Topics Anxiety Meditation
Keywords Obesity Internalized weight stigma
Registration NCT06087185
Key findings The mindfulness-based eating intervention produced no clear improvement in inhibitory control on the food Go/No-Go task but was associated with improvements across several psychological outcomes. Internalized weight stigma was positively associated with anxiety symptoms (B = 0.869) and negatively with body appreciation (B = -0.619); device use moderated the body appreciation-stigma association (B = 0.116), with body appreciation appearing more protective at lower device use.

Abstract

Background: There is a high prevalence of people living with obesity (LWO) and mental disorders, which could worsen stigma. Internalized weight stigma (IWS) impairs psychological functioning and eating behaviors. This study, therefore, evaluated the acute effects of a Mindfulness-based Eating (ME) intervention and the feasibility of incorporating IWS assessment into a randomized controlled trial for adults LWO and generalized anxiety disorder (GAD). It also explores associations between IWS, device use, and psychological outcomes.

Methods: Seventy adults LWO and GAD were randomized to a five-week ME group intervention (n = 36) or an asynchronous health educational video control (n = 34). The inhibitory control measured by the Go/No Go test was the primary RCT outcome. Post hoc feasibility outcomes were attendance and completion of the IWS assessment. The Weight Bias Internalization scale (WBIS) was applied alongside measures of body appreciation (BAS2), self-compassion (SCS), anxiety symptoms (GAD7), depressive symptoms (PHQ9), emotional dysregulation (DERS), shame (OAS), early memories (EMWSS), personality assessment (ER5FP), Mindful Eating (MEQ), binge eating (BES), impulsivity (BIS), and device use (smartphone/tablet). Associations were analyzed using correlation, regression and moderation; analyses of psychological outcomes were considered hypothesis-generating. NCT Number NCT06087185.

Findings: The ME group showed no clear improvement in inhibitory control on the food Go/No-Go task, but resulted in improvements across several psychological outcomes (p < 0.05). All participants completed the WBIS; retention in the RCT was 58.6%. WBIS was positively associated with GAD7 (B = 0.869, p = 0.005) and negatively with BAS2 (B = -0.619, p = 0.005). Device use moderated the association between BAS2 and WBIS at baseline (B = 0.116, p = 0.021), with body appreciation being more protective against IWS at lower device use.

Interpretation: ME shows promise for improving psychological outcomes linked to IWS. This study supports the feasibility of integrating IWS measures in trials examining obesity and GAD. Findings highlight the important effect of device use moderates the BAS2-IWS association. These findings can support clinicians and researchers in developing more effective, stigma-informed interventions for individuals LWO, particularly those with psychiatric disorders.

Funding: CAPES; CNPq; FIPE-HCPA (ROR: https://ror.org/010we4y38).

Comparable studies

Other randomized controlled trials on anxiety, most cited first.

Study Year Design Participants
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... 2006 Double-blind study n = 36
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Adults with advanced-stage cancer and anxiety 2010 Double-blind, placebo-controlled study n = 12

Citations in the library

Explore topics